Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Polycythemia Vera 2Thrombosis 1Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Glioma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Bites and Stings 1Adenocarcinoma Of Esophagus 1

Interventions

Temozolomide 52Radiotherapy 24Bevacizumab 23Radiation 10Magnetic Resonance Spectroscopy 7Lomustine 7Carmustine 7Radiosurgery 6Surgical Procedures, Operative 5Irinotecan 5Radiotherapy, Intensity-Modulated 4Nivolumab 4Ipilimumab 4Erlotinib Hydrochloride 4Cilengitide 4Aminolevulinic Acid 4vocimagene amiretrorepvec 3vitespin 3sargramostim 3poly ICLC 3pembrolizumab 3fluoromisonidazole 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3TPI-287 3O(6)-benzylguanine 3Granulocyte-Macrophage Colony-Stimulating Factor 3Flucytosine 3Dynamic Contrast Enhanced Magnetic Resonance Imaging 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Glioblastoma × Hydroxyurea × Clear all
NCT00290771 2011-05-16

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Novartis

Phase 2 Terminated
231 enrolled 12 charts
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡